Clinical trials sponsored by Institut Claudius Regaud

Phase breakdown

Conditions studied

Recruiting trials led by Institut Claudius Regaud

• Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
  NCT05867004 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
  NCT07233928 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
  NCT06904625 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Deciphering Mechanisms Underlying Cancer Immunogenicity
  NCT03958240 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
  NCT04513444 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
  NCT06917781 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
  NCT06967961 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
  NCT07195344 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
  NCT05378204 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
  NCT04740697 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Months and older · Sex: Female · 1 location

Common questions

How many trials is Institut Claudius Regaud recruiting for?

Institut Claudius Regaud is the lead sponsor of 10 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.